This site is intended for healthcare professionals
Respiratory Care
Declaration of sponsorship Novartis Pharma AG

Asthma Resources

Declaration of sponsorship Novartis Pharma AG
Read time: 400 mins
Last updated:18th Nov 2021
Published:23rd Jun 2020

Inhaled therapy science: a step forward in asthma

Welcome to Part 1 of the Novartis-sponsored symposium ‘Inhalation science and climate change: a step forward in asthma’. Part 2 can be viewed in the Sustainability section here.

In Part 1, ‘Inhaled therapy science: a step forward in asthma’, leading experts Professor David Price (chair), Professor Christine Jenkins, Professor Ken Chapman and Professor Christopher Lacksai discuss current challenges in inhaled asthma therapies. Updates to the GINA 2021 management cycle are examined, as well as the latest evidence and key clinical data in inhaled therapies, including indacaterol/glycopyrronium/mometasone furoate. Finally, the panel discuss the latest in digital innovation in respiratory care. Each presentation is followed by a lively panel discussion from all the faculty. Content produced in September 2021.

00:00 Welcome and introduction (David Price)
02:26 The management cycle: a major advance (Christine Jenkins)
13:54 Panel discussion
22:04 Stepping stones to asthma control: inhaled therapy science (Ken Chapman)
33:54 Panel discussion
36:55 Stepping stones to patient centricity: digital science (David Price, Christopher Licksai)
47:08 Panel discussion
53:46 Summary (David Price)
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

The new reality – better asthma care supported by digital health solutions (ERS 2020)

Using innovative Holopresence technology to provide a sense of real presence, we are pleased to bring you this exciting Novartis-sponsored symposium highlighting current and potential digital solutions to unmet needs with inhaled asthma therapies. The panel comprising Professor David Price (chair), Professor Kostantinos Kostikas and Dr Holger Woehrle discuss how digital innovations are currently being used for better informed decision-making and patient support.

Introduction

Professor David Price (Singapore) welcomes us to the symposium, introduces his co-presenters and provides an overview of the agenda

Digital solutions to real world challenges: addressing unmet needs with digital technology

Professor Price highlights the ongoing burden of asthma and COPD and describes the challenges of achieving good inhaler technique and adherence. He introduces digital solutions to these challenges such as telehealth and electronic sensor devices, which fit onto patients’ inhalers to monitor inhaler use.

Digital innovation: supporting the progress of asthma management


Professor Kostantinos Kostikas (Greece) provides an overview of digital solutions to support diagnosis, commenting that digital innovation is already part of clinical practice in respiratory medicine. Digital spirometry can provide useful information to clinicians and support clinical decision making while artificial intelligence has the potential to supplement human judgement for the benefit of patients.

Digital applications for current and future asthma management

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Webinars

Explore this section of the learning zone for asthma related spotlight webinars!

GINA 2021 Spotlight Webinar

This webinar provides a concise review of the updated GINA 2021 strategy recommendations and the implications for clinical practice. The review is followed by an interactive Q&A session with physicians from across the world.

Expert faculty:

Dr Mark Levy, United Kingdom

Professor van Zyl-Smit, South Africa

What’s new in GINA 2021?


Content produced in June 2021.

Implications for your clinical practice

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Resource from the PLATINUM clinical programme

View these animated infographics which provide an overview of IRIDIUM, ARGON, PALLADIUM AND QUARTZ, the four studies that make up the PLATINUM clinical programme. Learn about the LABA/LAMA/ICS and LABA/ICS combinations investigated in this programme, as well as the purpose, patients, endpoints and key results for each study.

The PLATINUM program was also discussed at the Novartis-sponsored Inhaled Symposium ERS 2020.
Content produced in September 2020.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

The IRIDIUM study


Professor David Halpin discusses the IRIDIUM Phase III study and its implications for clinical practice.
Content produced in July 2020.


The ARGON study


Professor Claus Vogelmeier discusses the ARGON Phase III study and its implications for clinical practice.
Content produced in July 2020.


The PALLADIUM study


Professor Richard van Zyl-Smit discusses the PALLADIUM Phase III study and its implications for clinical practice.
Content produced in July 2020.


Patient experience of asthma


Professor Christine Jenkins discusses the patient experience of asthma, including the burden of disease and treatment, and how this can be improved through patient-physician communication and shared decision making.
Content produced in August 2020.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Reconsidering the potential of inhaled therapies in asthma: Novartis Virtual Asthma Theatre

Welcome to this exciting symposium, originally scheduled to take place at the American Thoracic Society (ATS) Conference 2020 and now made available to you via Medthority as a series of short videos. 

These videos are intended for non-US healthcare professionals only.

Led by respiratory disease experts Professor David Price (chair), Professor Claus Vogelmeier and Professor Ken Chapman, learn how despite clinical advances reducing the number of asthma-related deaths, significant unmet needs remain. Treatment mismatch, poor adherence, and treatment misuse all contribute to the problem of uncontrolled asthma.

Given this context, you’ll be encouraged to reconsider the potential of inhaled therapies in the management of asthma, focussing on the treatment opportunity afforded by new inhaled, once-daily fixed-dose combinations. The scope for new devices and digital solutions to further improve treatment use and adherence in the asthma arena is also discussed. Finally, our faculty take a deep dive into some key management questions in a 10-minute Q&A session.

Introduction to the PLATINUM program

Professor Price describes the unmet need in asthma, highlighting that more than one-third of patients remain uncontrolled despite treatment. Professor Price goes on to introduce two new once-daily, inhaled fixed-dose combinations for asthma: indacaterol acetate and mometasone furoate (IND/MF); and indacaterol acetate, glycopyrronium bromide, and mometasone furoate (IND/GLY/MF).

A new LABA/ICS – a new treatment opportunity

Professor Vogelmeier shares data from the PALLADIUM trial, a 52-week, randomised double-blind, Phase III study. The study was primarily designed to compare IND/MF with MF and also included the active comparator salmeterol/fluticasone propionate (SAL/FLU) in secondary analyses.

Reconsidering the potential of inhaled therapies with a new, once-daily, fixed LAMA/LABA/ICS combination [Part 1]

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Welcome: